A Phase 3 interventional study of Tezepelumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 180 sites in 18 countries. Open to participants aged 13 Years to 81 Years. Per ClinicalTrials.gov, last updated 2023-06-06.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.
Among the 28 studies testing tezepelumab in Asthma, this one is the 2nd largest by enrollment, is one of 5 that started in 2019, is one of 16 in phase 3, and was the 8th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–55
AstraZeneca · Sites in China
Ages 12–80
AstraZeneca · Sites in United States, Argentina, Brazil and 19 more countries
Ages 5–11
Qianfoshan Hospital · Sites in China
Ages 18–75
Qilu Pharmaceutical Co., Ltd.
Ages 18–80
By country, each count listing its studies:
tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 13 Years to 81 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 5 started in 2019.
This study's enrollment of 951 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 121 across the 28 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 37th largest by enrollment of the 248 interventional ones that give a count, is one of 24 that started in 2019, is one of 121 in phase 3, and was the 241st registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing tezepelumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing tezepelumab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
Subjects who completed either D5180C00007 or D5180C00009 will be offered the opportunity to consent for the Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. The study consists of a treatment phase, followed by a follow-up phase where subjects will not receive IP. The length of the follow up phase is determined by which study the subject had previously completed.
Subjects who have not met investigational product discontinuation criteria and have attended the EOT visit in either study D5180C00007 or D5180C00009 will be offered the opportunity to consent for the Multicentre, Double-blind, Randomized, Parallel Group, Placebo Controlled, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab versus placebo in Adults and Adolescents (12 years of age and older) with a history of asthma exacerbations and inadequately controlled severe asthma receiving medium or high dose inhaled corticosteroid (ICS) plus at least one additional asthma controller medication with or without oral corticosteroids
Following treatment, subjects will enter a follow-up phase, determined by the predecessor study they had previously completed. Subjects will not receive IP during the follow-up phase. For subjects who entered the study from study D5180C00007 and did not meet IP Discontinuation criteria, the follow-up phase will extend from week 104 to Week 140. Subjects who entered the study from study D5180C00009 will have their follow-up phase extend to week 116.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To enter the extended follow-up phase of the study, the following inclusion criteria also apply:
Exclusion Criteria:
To enter the extended follow-up phase of the study (which extends from week 104 to week 140), the following exclusion criteria also apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tezepelumab subcutaneous injection
Biological: Tezepelumab
Placebo: Placebo subcutaneous injection
Other: Placebo
Tezepelumab subcutaneous injection
Placebo subcutaneous injection
Exposure Adjusted Incidence Rates of AEs/SAEs
Includes adverse events with an onset date between the date of first dose of IP in the predecessor and minimum (date of last dose of IP + 33 days, date of death, date of study withdrawal, day prior to start of another biologic). The analysis is based on the Safety Analysis Set. Exposure adjusted rates are defined as number of subjects with AEs divided by total time at risk across all subjects, multiplied by 100
Time frame: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Total Time at Risk
Includes time between the date of first dose of IP in the predecessor and minimum (date of last dose of IP + 33 days, date of death, date of study withdrawal, day prior to start of another biologic). The analysis is based on the Safety Analysis Set.
Time frame: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Annualized Asthma Exacerbation Rate (AAER)
The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF. The analysis is based on the primary population (Full Analysis Set)
Time frame: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Participants who completed treatment and attended end of treatment visit in predecessor studies NAVIGATOR (NCT03347279) or SOURCE (NCT03406078) were eligible for this long-term extension study. In the predecessor studies, a total of 1059 and 150 subjects were randomised and dosed in NAVIGATOR and SOURCE respectively. In DESTINATION, a total of 951 subjects (827 from NAVIGATOR and 124 from SOURCE) were randomised at 182 centres in 18 countries to receive treatment with tezepelumab or placebo.
| Milestone | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | NAVIGATOR Pbo to Teze | SOURCE Rand Teze | SOURCE Rand Pbo | SOURCE Pbo to Teze |
|---|---|---|---|---|---|---|
| Started | 529 | 532 | 0 | 74 | 76 | 0 |
| Received treatment | 528 | 531 | 0 | 74 | 76 | 0 |
| Completed | 513 | 509 | 0 | 68 | 73 | 0 |
| Not completed | 16 | 23 | 0 | 6 | 3 | 0 |
| Withdrew: Death | 0 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 2 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 8 | 15 | 0 | 5 | 2 | 0 |
| Withdrew: Did not receive treatment / non-compliance with protocol / did not complete safety follow-up visits | 3 | 4 | 0 | 0 | 0 | 0 |
| Milestone | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | NAVIGATOR Pbo to Teze | SOURCE Rand Teze | SOURCE Rand Pbo | SOURCE Pbo to Teze |
|---|---|---|---|---|---|---|
| Started | 415 | 206 | 206 | 60 | 32 | 32 |
| Received treatment | 415 | 206 | 205 | 60 | 32 | 32 |
| Completed | 400 | 200 | 198 | 58 | 28 | 31 |
| Not completed | 15 | 6 | 8 | 2 | 4 | 1 |
| Withdrew: Due to covid-19 pandemic | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Did not complete safety follow-up visits | 1 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 3 | 1 | 3 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Death | 8 | 2 | 2 | 1 | 0 | 0 |
The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF. The analysis is based on the primary population (Full Analysis Set)
| events per year | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | SOURCE Rand Teze | SOURCE Rand Pbo |
|---|---|---|---|---|
| Annualized Asthma Exacerbation Rate (AAER) | 0.82 (0.71 to 0.95) | 1.93 (1.70 to 2.20) | 1.07 (0.76 to 1.51) | 1.76 (1.27 to 2.45) |
Includes adverse events with an onset date between the date of first dose of IP in the predecessor and minimum (date of last dose of IP + 33 days, date of death, date of study withdrawal, day prior to start of another biologic). The analysis is based on the Safety Analysis Set. Exposure adjusted rates are defined as number of subjects with AEs divided by total time at risk across all subjects, multiplied by 100
| Patients with AEs per 100 person-years | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | SOURCE Rand Teze | SOURCE Rand Pbo |
|---|---|---|---|---|
| Any AE incidence rate | 49.62 | 62.66 | 47.15 | 69.97 |
| Any AE with outcome=death incidence rate | 0.76 | 0.14 | 1.55 | 0.00 |
| Any SAE incidence rate | 7.85 | 12.45 | 13.14 | 17.99 |
| Any AE leading to discontinuation of IP incidence rate | 1.64 | 3.00 | 1.55 | 2.00 |
Includes time between the date of first dose of IP in the predecessor and minimum (date of last dose of IP + 33 days, date of death, date of study withdrawal, day prior to start of another biologic). The analysis is based on the Safety Analysis Set.
| Year | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | SOURCE Rand Teze | SOURCE Rand Pbo |
|---|---|---|---|---|
| Total Time at Risk | 917.0 | 699.0 | 129.4 | 100.0 |
Collected over Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NAVIGATOR Rand Teze | 8/528 (1.5%) | 82/528 (15.5%) | 390/528 (73.9%) |
| NAVIGATOR Rand Pbo | 5/531 (0.9%) | 94/531 (17.7%) | 384/531 (72.3%) |
| NAVIGATOR Pbo to Teze | 1/206 (0.5%) | 17/206 (8.3%) | 98/206 (47.6%) |
| SOURCE Rand Teze | 2/74 (2.7%) | 18/74 (24.3%) | 53/74 (71.6%) |
| SOURCE Rand Pbo | 0/76 (0%) | 19/76 (25%) | 58/76 (76.3%) |
| SOURCE Pbo to Teze | 0/32 (0%) | 4/32 (12.5%) | 23/32 (71.9%) |
| Event | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | NAVIGATOR Pbo to Teze | SOURCE Rand Teze | SOURCE Rand Pbo | SOURCE Pbo to Teze |
|---|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 14/528 | 41/531 | 5/206 | 3/74 | 8/76 | 0/32 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 16/528 | 43/531 | 5/206 | 5/74 | 8/76 | 0/32 |
| Covid-19 pneumoniaInfections and infestations | 3/528 | 2/531 | 0/206 | 3/74 | 0/76 | 0/32 |
| EncephaloceleCongenital, familial and genetic disorders | 0/528 | 0/531 | 0/206 | 0/74 | 0/76 | 1/32 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/528 | 0/531 | 0/206 | 0/74 | 0/76 | 1/32 |
| Pneumonia haemophilusInfections and infestations | 0/528 | 0/531 | 0/206 | 0/74 | 0/76 | 1/32 |
| Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/528 | 0/531 | 0/206 | 0/74 | 0/76 | 1/32 |
| Intracranial aneurysmNervous system disorders | 0/528 | 0/531 | 0/206 | 0/74 | 0/76 | 1/32 |
| Lumbar radiculopathyNervous system disorders | 0/528 | 0/531 | 0/206 | 0/74 | 0/76 | 1/32 |
| Transient ischaemic attackNervous system disorders | 1/528 | 1/531 | 0/206 | 0/74 | 0/76 | 1/32 |
| Event | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | NAVIGATOR Pbo to Teze | SOURCE Rand Teze | SOURCE Rand Pbo | SOURCE Pbo to Teze |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 130/528 | 124/531 | 21/206 | 18/74 | 22/76 | 7/32 |
| Upper respiratory tract infectionInfections and infestations | 72/528 | 91/531 | 6/206 | 12/74 | 9/76 | 0/32 |
| HeadacheNervous system disorders | 58/528 | 54/531 | 13/206 | 9/74 | 10/76 | 1/32 |
| HypertensionVascular disorders | 30/528 | 26/531 | 4/206 | 5/74 | 7/76 | 4/32 |
| Covid-19Infections and infestations | 7/528 | 8/531 | 10/206 | 5/74 | 1/76 | 4/32 |
| BronchitisInfections and infestations | 29/528 | 39/531 | 2/206 | 9/74 | 3/76 | 0/32 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 14/528 | 25/531 | 2/206 | 6/74 | 9/76 | 0/32 |
| Bronchitis bacterialInfections and infestations | 30/528 | 19/531 | 3/206 | 8/74 | 7/76 | 3/32 |
| SinusitisInfections and infestations | 30/528 | 43/531 | 5/206 | 2/74 | 5/76 | 1/32 |
| Oral candidiasisInfections and infestations | 12/528 | 15/531 | 2/206 | 5/74 | 6/76 | 2/32 |
| Age, Categorical(Participants) | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | SOURCE Rand Teze | SOURCE Rand Pbo | Total |
|---|---|---|---|---|---|
| <=18 years | 41 | 41 | 0 | 0 | 82 |
| Between 18 and 65 years | 391 | 416 | 58 | 62 | 927 |
| >=65 years | 96 | 74 | 16 | 14 | 200 |
| Age, Continuous(Years) | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | SOURCE Rand Teze | SOURCE Rand Pbo | Total |
|---|---|---|---|---|---|
| Mean | 49.9 ± 16.3 | 49.0 ± 15.9 | 53.5 ± 12.1 | 53.4 ± 11.9 | 49.9 ± 15.7 |
| Sex: Female, Male(Participants) | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | SOURCE Rand Teze | SOURCE Rand Pbo | Total |
|---|---|---|---|---|---|
| Female | 335 | 337 | 49 | 45 | 766 |
| Male | 193 | 194 | 25 | 31 | 443 |
| Race/Ethnicity, Customized(Participants) | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | SOURCE Rand Teze | SOURCE Rand Pbo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 83 | 81 | 10 | 14 | 188 |
| Not Hispanic or Latino | 445 | 450 | 64 | 62 | 1021 |
| Race/Ethnicity, Customized(Participants) | NAVIGATOR Rand Teze | NAVIGATOR Rand Pbo | SOURCE Rand Teze | SOURCE Rand Pbo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 146 | 149 | 11 | 11 | 317 |
| Black of African American | 30 | 31 | 1 | 0 | 62 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Other | 19 | 23 | 0 | 1 | 43 |
| White | 332 | 327 | 62 | 64 | 785 |
Showing the first 100 of 180 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2019 to primary completion in Oct 2021, 33 months.
Results were first posted in Feb 2023, 1 year 3 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 33 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab